Hence, rapamycin can be classified as a substrate for transport by P-glycoprotein (Kerr et al, 2001), as a consequence tumours overexpressing P-glycoprotein (MDR1) may be resistant to rapamycins (Figure 1A). This evidence concerns the gene ABCB1 and neoplasm.